In order to address PCa tumor heterogeneity, given that their expression is extremely heterogeneous, the utilization of both pharmacophores has been suggested (27), specifically, the utilization of heterodimeric radiotracer ligands able to target both PSMA and GRPr (28). The gene discussed is GRPR; the disease is posterior cortical atrophy.